NEWS

Biden's Attempts to Lower Drug Costs Are Sabotaging Biosimilar Competition and Are Destined For Failure

The FDA approved 55 new drugs in 2023 — up substantially from 2022's 37 approvals, and barely behind the all-time record of 59 set in...

The Biden administration should not support a WTO petition to strip IP protections from Covid-19 treatments

The Biden administration may soon double down on one of its gravest mistakes. In 2022, it supported a petition before the World Trade...

The Bayh-Dole Act works. It’s not time to change it.

Forty-three years ago, a young U.S. Sen. Joe Biden voted for a transformative policy reform that subsequently catalyzed upwards of $2...

Biden Administration’s Threat to Pharmaceutical Innovation Endangers Lives

The idea that the government could forcibly seize ownership of a groundbreaking invention you created is chilling. But that is the...

CMS Finalizes Policy to Facilitate Faster Biosimilar Uptake but Follow-on Policies and Actions Still Needed

The Centers for Medicare & Medicaid Services (CMS) recently released a final rule allowing Medicare Advantage and Part D health plans to...

Statement by We Work For Health Executive Director Dan Leonard on World IP Day

FOR IMMEDIATE RELEASE April 26, 2024 WASHINGTON, D.C. – We Work For Health Executive Director Dan Leonard issued the following statement...

Commonsense Policies Needed to Lower Healthcare Costs and Improve Patient Access While Protecting Drug Development Pipeline

Today, President Biden highlighted the administration’s current and future efforts to lower healthcare costs. The good news is recent...

Paths to Progress: Understanding Policy’s Broad Impact on US Leadership in Biopharma

We Work For Health recently convened a conversation to explore the impact policy decisions have on the biopharmaceutical industry and...